(Press-News.org) A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body’s immune system to target and eliminate cancer cells appeared to reduce the risk of distant metastases for an aggressive form of skin cancer when given immediately after surgery, but did not significantly reduce the overall risk of recurrence, which was a co-primary endpoint of the trial. The randomized phase 3 STAMP trial (EA6174) is the largest clinical study to date evaluating pembrolizumab, an anti-PD-1 therapy, as adjuvant therapy for Merkel cell carcinoma following surgical removal of the tumor.
The STAMP trial found that after two years, 73% of patients receiving pembrolizumab showed no cancer recurrence, compared with 66% among those who did not receive the drug. Although this difference did not reach statistical significance, patients receiving pembrolizumab had a 42% lower risk of developing distant metastases—cancer spreading to organs such as the liver, lungs, or bones – which was a secondary objective of the study.
“The STAMP trial provides the first evidence that immunotherapy with pembrolizumab after surgery may help people with Merkel cell carcinoma by preventing their cancer from returning in organs considered distant from the site of the original disease,” said lead investigator Janice M. Mehnert, MD, co-chair of the ECOG-ACRIN Melanoma Committee and director of Melanoma and Cutaneous Medical Oncology at NYU Langone Health’s Perlmutter Cancer Center. “This is much-needed good news for people who are living with the highly aggressive cancer that is Merkel cell carcinoma,” Dr. Mehnert added.
Merkel cell carcinoma is a fast-growing cancer that begins in the skin’s sensory cells, often appearing as a single, painless bump on sun-exposed areas. Although skin cancer is by far the most common type of cancer in the United States, Merkel cell carcinoma, also called neuroendocrine carcinoma of the skin, is highly uncommon, occurring in no more than three out of one million people annually. It is extremely aggressive, with fewer than half of patients surviving 5 years after diagnosis.
The phase 3 multicenter study (NCT03712605) was conducted from 2018 to 2023 and involved 293 patients whose tumors had been surgically removed. Of these, 147 were randomly assigned to receive pembrolizumab infusions after surgery, while 146 were observed without additional drug therapy. Some participants also received radiation as advised by their physicians.
Because Merkel cell carcinoma is a rare tumor, Mehnert emphasized that national collaboration is essential for recruiting patients for a trial of this scale. Supported by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), ECOG-ACRIN opened the study at over five hundred hospitals and cancer centers nationwide, through the NCI’s National Clinical Trials Network.
Pembrolizumab is a type of immunotherapy known as a PD-1 inhibitor. Its mechanism of action involves blocking the PD-1 protein receptor, which cancer cells exploit to evade immune attack. Pembrolizumab allows immune cells to detect and attack tumors more effectively. It is approved by the U.S. Food and Drug Administration (brand name KEYTRUDA®) for treating recurrent locally advanced or metastatic Merkel cell carcinoma.
Overall survival, the other co-primary endpoint of the trial, continues to be followed and will be reported at a later date.
Dr. Mehnert will present the trial at the European Society for Medical Oncology (ESMO) 2025 Congress on Monday, October 20 in Berlin, Germany.
About ECOG-ACRIN
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a membership-based scientific organization known for advancing precision medicine and biomarker research through its leadership of major national clinical trials that integrate innovative genomic approaches. Nearly 21,000 member researchers and advocates from approximately 1,400 academic medical centers and community hospitals collaborate across over forty scientific committees to design studies spanning the cancer care spectrum, from early detection to management of advanced disease.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
END
Immunotherapy after surgery shows potential in preventing the spread of aggressive skin cancer
2025-10-20
ELSE PRESS RELEASES FROM THIS DATE:
What is the extent of disparities in cancer clinical trials among low- and middle-income countries?
2025-10-20
New research reveals that the number and complexity of cancer clinical trials since 2001 have varied across low- and middle-income countries (LMICs), with economic growth contributing to disparities, but only to a certain extent. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
Although LMICs are expected to experience the greatest global burden of cancer in the coming years, cancer clinical trials are disproportionally concentrated in high-income countries. Because evidence suggests that LMICs have increased the number of cancer clinical trials over the last few decades, researchers investigated disparities ...
Invisible poison: Airborne mercury from gold mining is contaminating African food crops, new study warns
2025-10-20
In a recent study published today in the European Geosciences Union (EGU) journal Biogeosciences, scientists have confirmed that mercury pollution from artisanal and small-scale gold mining (ASGM) is contaminating food crops not through the soil, as previously believed, but directly from the air. Driven by the surging price of gold, which has increased by more than tenfold since 2000, the rapid expansion of unregulated mining in these regions raises urgent questions about food security, human health, and environmental justice
The study, conducted by an international team of scientists led by Excellent ...
Nearly half of Finns with chronic conditions find medication therapy a burden
2025-10-20
According to a recent study, 44% of people with chronic conditions who responded to a population-based survey experienced medication-related burden (MRB). The burden was most common among people with diabetes, heart disease, rheumatic disease or some other musculoskeletal disorder. The greatest burden was caused by factors associated with health care, such as fragmented care and the cost of medicines, as well as adverse drug reactions or concerns about them.
“Other factors linked with MRB were poor health status, limits on functional capacity and low income,” says Pharmacist and Doctoral Researcher Heidi Mikkola from the School of Pharmacy at the University of ...
Do animals fall for optical illusions? What fish and birds can teach us about perception
2025-10-20
Have you ever looked at two circles of exactly the same size and sworn one was larger? If so, your eyes have been tricked by the Ebbinghaus illusion, a classic example of how context can shape what we see. Place a circle among other smaller circles, and it seems bigger; place it among larger ones, and it shrinks before our eyes. This illusion fascinates psychologists because it reveals that perception is not a mirror of the outside world but a clever construction of the brain.
But here is the question that inspired our study: do other animals fall for the same tricks? If a tiny fish or a bird perceives ...
New guideline emphasizes conversations about mood, mental health between patients and clinicians
2025-10-20
Depression is a mental illness, and support for depression can improve emotions, thoughts, and well-being. A new guideline from the Canadian Task Force on Preventive Health Care recommends that patients aged 18 and older talk to their health care providers about depression rather than undergo routine screening with standard tools, like questionnaires. The guideline is published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250237.
In Canada, depression is common, with about 1 in 10 people (without bipolar disorder) experiencing depression in their lifetimes. It negatively affects how a person ...
Children’s Hospital of Philadelphia researchers observe significant reduction in diagnosis of food allergies following expert guidelines encouraging early peanut exposure
2025-10-20
Philadelphia, October 20, 2025 – Peanuts represent one of the most common causes of immunoglobulin E (IgE)-mediated, or anaphylactic, food allergies in children, yet a landmark study found that early introduction of peanut to infants may lower their risk of developing this allergy. Now, a new study from researchers from Children’s Hospital of Philadelphia (CHOP) has shown that the rates of diagnosis of peanut and other IgE-mediated food allergies have declined since the adoption of guidelines encouraging early introduction practices.
The findings, published today ...
ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma
2025-10-19
VT3989 is a first-in-class YAP-TEAD inhibitor from Vivace Therapeutics that is currently in Phase I/II trials for patients with advanced solid tumors, with a focus on refractory mesothelioma
In this trial, VT3989 demonstrated notable antitumor activity, with a disease control rate of 86% at the clinically optimized dosing levels
These data provide the first clinical proof-of-concept for effectively drugging the Hippo-YAP-TEAD pathway
VT3989 was awarded Orphan Drug Designation and Fast Track Designation for the treatment of mesothelioma by the FDA
BERLIN, OCTOBER 19, 2025 ― The first-in-class YAP-TEAD inhibitor ...
Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer
2025-10-19
Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine, researchers have found.
The observation by researchers at the University of Florida and the University of Texas MD Anderson Cancer Center is a defining moment in a decade-plus of research testing mRNA-based therapeutics designed to “wake up” the immune system against cancer. Building on a previous UF study, the observation also marks a significant step toward a long-awaited universal cancer vaccine to ...
ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy
2025-10-19
Cancer patients who received mRNA COVID vaccines within 100 days of starting immunotherapy were twice as likely to be alive three years after treatment as those who never received a vaccine
These findings have prompted a randomized Phase III trial to determine if mRNA COVID vaccines should be part of the standard of care for this type of therapy
If validated, findings could significantly increase the number of patients who benefit from immunotherapy
BERLIN, OCTOBER 19, 2025 ― Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after beginning ...
Drug combo cuts risk of death in advanced prostate cancer by 40%
2025-10-19
Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.
The combination therapy, which adds a drug called enzalutamide to commonly prescribed hormone therapy, reduced deaths in patients with recurrent prostate cancer after surgery or radiation for whom other treatments are no longer an option. The trial results were published in The New England Journal of Medicine (NEJM) with simultaneous presentation during the European Society for Medical Oncology Congress (ESMO) Oct. 19 in Berlin.
“After ...